424 related articles for article (PubMed ID: 17391418)
1. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model.
Cipriano LE; Rupar CA; Zaric GS
Value Health; 2007; 10(2):83-97. PubMed ID: 17391418
[TBL] [Abstract][Full Text] [Related]
2. Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK
Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160
[TBL] [Abstract][Full Text] [Related]
3. An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand.
Thiboonboon K; Leelahavarong P; Wattanasirichaigoon D; Vatanavicharn N; Wasant P; Shotelersuk V; Pangkanon S; Kuptanon C; Chaisomchit S; Teerawattananon Y
PLoS One; 2015; 10(8):e0134782. PubMed ID: 26258410
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.
Pandor A; Eastham J; Beverley C; Chilcott J; Paisley S
Health Technol Assess; 2004 Mar; 8(12):iii, 1-121. PubMed ID: 14982654
[TBL] [Abstract][Full Text] [Related]
5. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel.
Insinga RP; Laessig RH; Hoffman GL
J Pediatr; 2002 Oct; 141(4):524-31. PubMed ID: 12378192
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France.
Hamers FF; Rumeau-Pichon C
BMC Pediatr; 2012 Jun; 12():60. PubMed ID: 22681855
[TBL] [Abstract][Full Text] [Related]
7. Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland.
Autti-Rämö I; Mäkelä M; Sintonen H; Koskinen H; Laajalahti L; Halila R; Kääriäinen H; Lapatto R; Näntö-Salonen K; Pulkki K; Renlund M; Salo M; Tyni T
Acta Paediatr; 2005 Aug; 94(8):1126-36. PubMed ID: 16188860
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive cost-utility analysis of newborn screening strategies.
Carroll AE; Downs SM
Pediatrics; 2006 May; 117(5 Pt 2):S287-95. PubMed ID: 16735255
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of tandem mass spectrometry newborn screening in Australia.
Norman R; Haas M; Chaplin M; Joy P; Wilcken B
Pediatrics; 2009 Feb; 123(2):451-7. PubMed ID: 19171609
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of expanded newborn screening in Texas.
Tiwana SK; Rascati KL; Park H
Value Health; 2012; 15(5):613-21. PubMed ID: 22867769
[TBL] [Abstract][Full Text] [Related]
11. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
[TBL] [Abstract][Full Text] [Related]
12. Newborn screening for inborn errors of metabolism: a systematic review.
Seymour CA; Thomason MJ; Chalmers RA; Addison GM; Bain MD; Cockburn F; Littlejohns P; Lord J; Wilcox AH
Health Technol Assess; 1997; 1(11):i-iv, 1-95. PubMed ID: 9483156
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of targeted or universal screening for vasa praevia at 18-20 weeks of gestation in Ontario.
Cipriano LE; Barth WH; Zaric GS
BJOG; 2010 Aug; 117(9):1108-18. PubMed ID: 20560948
[TBL] [Abstract][Full Text] [Related]
14. Economics of tandem mass spectrometry screening of neonatal inherited disorders.
Pandor A; Eastham J; Chilcott J; Paisley S; Beverley C
Int J Technol Assess Health Care; 2006; 22(3):321-6. PubMed ID: 16984060
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry.
Tran K; Banerjee S; Li H; Noorani HZ; Mensinkai S; Dooley K
Clin Biochem; 2007 Feb; 40(3-4):235-41. PubMed ID: 17222812
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of tandem mass spectrometry screening in California.
Feuchtbaum L; Cunningham G
Pediatrics; 2006 May; 117(5 Pt 2):S280-6. PubMed ID: 16735254
[TBL] [Abstract][Full Text] [Related]
17. Cost-benefit analysis: newborn screening for inborn errors of metabolism in Lebanon.
Khneisser I; Adib S; Assaad S; Megarbane A; Karam P
J Med Screen; 2015 Dec; 22(4):182-6. PubMed ID: 26062758
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of The Netherlands.
van der Hilst CS; Derks TG; Reijngoud DJ; Smit GP; TenVergert EM
J Pediatr; 2007 Aug; 151(2):115-20, 120.e1-3. PubMed ID: 17643759
[TBL] [Abstract][Full Text] [Related]
19. [Tandem mass spectrometry as screening for inborn errors of metabolism].
Campos H D
Rev Med Chil; 2011 Oct; 139(10):1356-64. PubMed ID: 22286738
[TBL] [Abstract][Full Text] [Related]
20. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening.
Schoen EJ; Baker JC; Colby CJ; To TT
Pediatrics; 2002 Oct; 110(4):781-6. PubMed ID: 12359795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
